Yahoo · Sep 4, 2026
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.2% and
IM
NASDAQ · IMRN
Immuron Limited
Healthcare · Biotechnology
$1.19
Down-$0.01 (-0.84%)
Updated Sep 18, 2026, 1:08 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 6.09M
- P/E ratio
- -1.74
- Dividend yield
- 0.00%
- 52-week range
- $0.70 – $1.99
- Volume
- 149K
- Avg. volume
- 545.45K
Price performance
IMRN price history
1M range · 19 trading sessions · Daily adjusted prices
IMRN closed at $1.19 after 19 trading sessions, up 0.85% for the selected period.
- Last close
- $1.19
- Period change
- +0.85%
- Period low
- $1.07
- Period high
- $1.84
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $1.24 | $1.285 | $1.19 | $1.19 | 149K |
| Sep 15, 2026 | $1.34 | $1.40 | $1.23 | $1.24 | 286.01K |
| Sep 14, 2026 | $1.37 | $1.415 | $1.35 | $1.40 | 156.96K |
| Sep 11, 2026 | $1.60 | $1.67 | $1.42 | $1.45 | 468.85K |
| Sep 10, 2026 | $1.725 | $1.76 | $1.58 | $1.63 | 532.81K |
| Sep 9, 2026 | $1.77 | $1.85 | $1.76 | $1.76 | 851.19K |
| Sep 8, 2026 | $1.765 | $1.92 | $1.61 | $1.84 | 4.28M |
| Sep 4, 2026 | $1.81 | $1.99 | $1.54 | $1.80 | 123.14M |
| Sep 3, 2026 | $1.15 | $1.1698 | $1.11 | $1.11 | 3.79K |
| Sep 2, 2026 | $1.08 | $1.17 | $1.07 | $1.17 | 12.78K |
| Sep 1, 2026 | $1.16 | $1.16 | $1.06 | $1.07 | 14K |
| Aug 31, 2026 | $1.15 | $1.15 | $1.11 | $1.11 | 21.94K |
| Aug 28, 2026 | $1.15 | $1.18 | $1.15 | $1.15 | 7K |
| Aug 27, 2026 | $1.175 | $1.175 | $1.145 | $1.165 | 4.26K |
| Aug 26, 2026 | $1.12 | $1.1481 | $1.12 | $1.14 | 3.4K |
| Aug 25, 2026 | $1.13 | $1.165 | $1.1203 | $1.14 | 12.12K |
| Aug 24, 2026 | $1.1405 | $1.1405 | $1.12 | $1.12 | 5.2K |
| Aug 21, 2026 | $1.17 | $1.175 | $1.11 | $1.12 | 7.95K |
| Aug 20, 2026 | $1.12 | $1.18 | $1.11 | $1.18 | 9.87K |
Latest IMRN news
The latest Smart Investors Daily articles mentioning IMRN.
Stock researchCompany · Overview
IMRN research
Overview
Company profile and research snapshot.
Company profile
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 18, 2017 | H.C. Wainwright | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
IMRN Stock Skyrockets 60%, Heads For Best Day In Over 2 Years – What’s Driving The Super Rally Today?
Immuron signed an agreement with Sweden’s Calmino Group to distribute digestive-health product Proibs in the U.S
Yahoo · Sep 4, 2026
Immuron Plans U.S. PROIBS Launch Under Exclusive Distribution Agreement
Immuron (NASDAQ:IMRN) has secured exclusive U. S.
Benzinga · Sep 4, 2026
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results
U.S. stocks fell as August jobs beat estimates; oil, gold and silver declined. Immuron, Quanex and AOUT surged, while GWRE, LULU and PATH dropped.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
